Braze, Inc. (BRZE) Financial Statements
Braze, Inc. (BRZE) reported trailing twelve-month revenue of $834.2M (up 27.4% year on year) and net income of -$113.0M as of 2026-07-31, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $80.2M.
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
BRZEBraze, Inc.Follow BRZE — free
—
Price chart with a free account
- Market cap
- 5.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 7 Dec, in 44 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jul 26.
| Line | FY2022 Jan 22 | FY2023 Jan 23 | FY2024 Jan 24 | FY2025 Jan 25 | FY2026 Jan 26 | TTM Jul 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.24 | 0.36 | 0.47 | 0.59 | 0.74 | 0.83 | |
| Gross profit | 0.16 | 0.24 | 0.32 | 0.41 | 0.50 | 0.55 | |
| Research & development | 0.06 | 0.10 | 0.12 | 0.13 | 0.17 | 0.18 | |
| Operating income | -0.08 | -0.15 | -0.14 | -0.12 | -0.14 | -0.11 | |
| Pre-tax income | -0.08 | -0.14 | -0.13 | -0.10 | -0.13 | -0.10 | |
| Income tax | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Net income | -0.08 | -0.14 | -0.13 | -0.10 | -0.13 | -0.11 | |
| Diluted EPS ($) | -2.20 | -1.47 | -1.32 | -1.02 | -1.22 | -1.03 | |
| Diluted shares (bn) | 0.035 | 0.095 | 0.098 | 0.102 | 0.108 | — |
USD billions · SEC XBRL
Braze, Inc. — questions
- What is Braze, Inc.'s revenue?
- $834.2M over the twelve months to 2026-07-31, up 27.4% year on year, from its 10-Q and 10-K filings.
- What is Braze, Inc.'s net income?
- -$113.0M over the twelve months to 2026-07-31.
- What is Braze, Inc.'s free cash flow?
- $80.2M over the twelve months to 2026-07-31.
- What are Braze, Inc.'s diluted earnings per share?
- $-1.03 over the twelve months to 2026-07-31.
Every figure on this page comes from Braze, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.